biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases.

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

CEO

Jon Stonehouse

biocryst.com/ →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

Rolls-Royce and airlines fall as Iran war threatens jet fuel supplies

Par Petroleum (PARR) Surges 5.8%: Is This an Indication of Further Gains?

CVR (CVI) Soars 5.3%: Is Further Upside Left in the Stock?

Goldman Lifts Oil Price Forecast on Longer Hormuz Disruption

Vistry Group: Alas, Patience Needed All Over Again

Alm. Brand A/S share buy-back program is concluded - transactions week 12

LTM Expands BlueVerse™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering

BOSS Zhipin Continues Share Repurchase Program, Reinforcing Commitment to Shareholder Returns

Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment

Precious metals miners sink as gold and silver prices tumble

Absci Corporation (ABSI) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Danone to Buy Nutrition Company Huel

Gold's Worst Week In 40 Years: What This Means For Your Gold Strategy

Palantir's Stock Valuation Still Looks Absurd. Here's Why Investors Keep Buying It Anyway.

Prediction: This Will Be Micron's Stock Price by Late 2027

Empire Metals hails transformational year at giant Australian titanium project

Elon Musk Unveils Terafab Project. What It Means for Tesla Stock.

Roche Halts Development of Drug Candidate for Muscle Diseases, Chugai Says

Nexra Wins Additional Near-Term Contract in Taiwan

Monte dei Paschi's board to challenge CEO's role, sources say

About